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Abstract 
Problem: The lectin pathway of the complement system may be involved in the 
pathogenesis of preeclampsia. We aimed to investigate changes in serum concentrations of 
a broad range of lectin pathway proteins during normal pregnancy and their association with 
preeclampsia, placental infarctions and intrauterine growth restriction (IUGR). 
Method of study: We included 51 women with normotensive pregnancies and 54 women 
with pregnancies complicated by preeclampsia. Blood samples were obtained at gestational 
weeks 16, 33, 37, and after delivery for the normotensive pregnant women and before and 
after delivery for women with preeclampsia. Mannose-binding lectin (MBL), H- and M-ficolin, 
collectin liver-1 (CL-L1), MBL-associated serine proteases (MASPs)-1, -2 and -3 and MBL-
associated proteins of 19 (MAp19) and 44 (MAp44) kDa were analysed. Clinical information 
was obtained from medical records. The placentae were examined by two experienced 
perinatal pathologists. 
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Results: Lectin pathway protein concentrations generally increased during normal 
pregnancy and decreased after delivery in both normotensive pregnant women and women 
with preeclampsia. Exceptions were MASP-3 which increased after delivery in both groups 
(p<0.0001) and H-ficolin which increased after delivery in preeclampsia (p<0.0001). H-ficolin 
(p<0.0001), M-ficolin (p=0.005), and MASP-3 (p=0.03) concentrations were lower in women 
with preeclampsia than in normotensive pregnant women. Low MASP-3 concentrations were 
associated with placental infarction (p=0.03) and IUGR (p=0.04). Low H-ficolin 
concentrations were associated with IUGR (p<0.01). 
Conclusions: In general, lectin pathway protein serum concentrations increased during 
normal pregnancy. H-ficolin and MASP-3 may be involved in the pathophysiology of 
preeclampsia and IUGR and could be potential future preeclampsia biomarkers. 
 
Keywords (MeSH): “Complement Pathway, Mannose-Binding Lectin”; “Ficolin”; “Mannose-
Binding Protein-Associated Serine Proteases”; “Pre-Eclampsia”; “Intrauterine Growth 
Restriction” 
 
Introduction 
Preeclampsia affects approximately 5% of all pregnancies worldwide1 and is a major cause 
of maternal and perinatal morbidity and mortality.2 The condition is characterized by new-
onset hypertension after the 20th gestational week and proteinuria and is associated with 
potentially life-threatening maternal organ dysfunction as well as intrauterine growth 
restriction (IUGR) and preterm birth.3,4 The cause of preeclampsia is debated, but an 
abnormal trophoblast invasion and impaired remodelling of uterine spiral arteries are 
considered the main pathogenetic factors.5 Furthermore, preeclampsia is characterised by 
enhanced apoptotic6 and inflammatory changes7 in the placenta as well as excess placental 
infarction.8 
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A dysregulated maternal immune response is regarded a key factor in the abnormal 
placental establishment in early pregnancy,9 and the complement system has been 
suggested as an important contributor,10 as signs of systemic increased complement 
activation in preeclampsia with increased classical and terminal pathway activity have been 
described.11 The complement system is part of the innate immune system, providing a first 
line defence against infection. The system is also an intimate part of the recognition and 
clearing of altered-self structures, e.g. as may occur through pregnancies.12,13 Complement 
activation generates inflammatory mediators which facilitate a crucial danger signal to 
surrounding cells and migrating leucocytes.14 The lectin pathway, which is the most recently 
described complement activation pathway, has gained much interest in the development of 
preeclampsia and IUGR.15-21 The lectin pathway consists of the pattern recognition 
molecules mannose-binding lectin (MBL), ficolins (H-, L- and M-) and collectins liver-1 (CL-
L1) and kidney-1 (CL-K1), together with the MBL-associated serine proteases (MASPs)-1, -2 
and -3 and the regulatory MBL-associated proteins of 19 kDa (MAp19) and 44 kDa 
(MAp44).22 MBL may be directly involved in the impairment of spiral artery remodelling and 
trophoblast invasion in early pregnancy.15,16 Furthermore, the pattern recognition molecules 
recognise not only pathogens but also necrotic or apoptotic cells.12,13 Thus, pattern 
recognition and subsequent complement activation in the preeclampsia-affected placenta 
may contribute to inflammation and placental insufficiency later in pregnancy. Finally, MASP-
1 and -2 enhance prothrombin activation, fibrin formation and clot stabilisation in vitro.23-25 
This may aggravate placental infarction and further impair placental function.   
 Increased circulating MBL concentrations have been reported for pregnant women with 
preeclampsia compared with normotensive pregnant women.17,18 One study found an 
association between high MBL serum concentration and impaired placental perfusion.18 
Others found that MBL2 genotypes normally causing high MBL serum concentrations were 
more prevalent in women with preeclampsia than in healthy pregnant women.19,20 These 
findings indicate a protective effect of low serum-MBL on preeclampsia risk. However, this 
was contradicted by a study which found a higher prevalence of MBL2 genotypes associated 
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with low MBL serum concentrations in preeclampsia than in normotensive pregnancy.26 
Other studies reported no differences in MBL serum concentrations27-29 or MBL2 genotype 
distribution30 between women with preeclampsia and normotensive pregnant women. 
Concerning other lectin pathway proteins, two studies reported lower serum 
concentrations of H- and L-ficolin in preeclampsia than in normotensive pregnancy.21,27 
Finally, a recent study reported that several MASP1 polymorphisms which may impair 
MASP-1 synthesis were associated with a higher risk of preeclampsia.31 Serum 
concentrations of MASP-1, -2 or -3, M-ficolin or CL-L1/CL-K1 have not been investigated 
previously in women with preeclampsia. Thus, the association between MBL and 
preeclampsia is still not fully elucidated, while the role of other lectin pathway proteins in 
preeclampsia is not well investigated. 
The present study aimed to investigate changes in serum concentrations of lectin 
pathway proteins during normal pregnancy and their possible association with the 
development of preeclampsia, placental infarctions and IUGR. 
 
Materials and methods 
Design and study population 
The present study included two groups of pregnant women; a) normotensive pregnant 
women and b) pregnant women with preeclampsia. The women were prospectively enrolled 
at the Departments of Gynaecology and Obstetrics, Hillerød Hospital and Glostrup Hospital, 
Denmark, from January 2004 to August 2006 as part of a previous study.32 Normotensive 
pregnant women were enrolled at their routine antenatal care visit at gestational age (GA) 
16-17 weeks and followed during pregnancy and after delivery. Consecutive blood samples 
were obtained at GA 16, 33 and 37 (±1 week) and 1 month after delivery. A total of 580 
women were enrolled in the original cohort, with serum available from 51 normotensive, 
healthy pregnant women for the present study. Pregnant women with suspected 
preeclampsia were enrolled from the obstetric department when referred for acute or 
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subacute assessment. Only women with a confirmed diagnosis of preeclampsia were 
included in the final cohort. Blood samples were obtained at inclusion (median GA 35+4) and 
after delivery (see Table 1). Sixty-one women were included, with serum available from 54 
women for the present study.  
All participants gave written informed consent to be included in the original study, which 
was carried out in accordance with the Helsinki Declaration and approved by the Committee 
on Biomedical Research Ethics of the Capital Region of Denmark (record no: H-Ø-2005-2-
04) and the Danish Data Protection Agency (record no: 2010-41-5119). All health care data 
were fully anonymised for the present study. 
Lectin pathway protein concentrations in healthy, non-pregnant female blood donors 
(n=149), enrolled from the blood bank at the Department of Clinical Immunology, Aarhus 
University Hospital, Denmark, have previously been described by our group.33 
 
Clinical outcomes 
Danish preeclampsia patients are diagnosed according to the criteria stated in the American 
College of Obstetricians and Gynecologists’ task force report on hypertension in pregnancy:3 
1) blood pressure ≥140 mmHg systolic and/or ≥90 mmHg diastolic measured on at least two 
separate occasions after GA 20 and 2) proteinuria >300 mg/24 h or protein/creatinine ratio 
>0.3. Severe preeclampsia was defined as a blood pressure ≥160 mmHg systolic and/or 
≥110 mmHg diastolic on two separate occasions or one or more symptoms or laboratory 
findings related to renal, hepatic, pulmonary or cerebral dysfunction or the presence of 
HELLP (haemolysis, elevated liver enzymes and low platelet count).3 IUGR was defined as 
foetal weight >2 standard deviations (equal to -22%) below mean weight for GA using 
Marsal’s growth charts as reference.34 
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Placental pathology 
Placentae obtained from study participants were fixated in 10% formalin immediately after 
delivery and transported to the Department of Pathology, Hillerød Hospital, Denmark. 
Placental examination was performed by one of two experienced perinatal pathologists 
affiliated to the project. Both were blinded to the clinical outcomes. Infarction of up to 5% of 
the placental parenchyma is considered a normal finding in full-term healthy pregnancies;4 
therefore we defined ≥10% infarction of the total placental parenchyma as clinically 
significant. 
Data on placental fibrin deposition and inflammation were available, but since the number of 
events were low (fibrin deposition, n=3; inflammation, n=4), statistical analysis was not 
performed for these variables. 
 
Lectin pathway protein analysis 
Blood samples were drawn in 5 ml serum tubes (Venosafe Z Serum Clot Activator, Terumo 
Europe, Belgium) and centrifuged at 2,773 g for 20 minutes at 4°C. Serum was stored at -
80°C within two hours of sampling. Lectin pathway protein concentrations were analysed 
with time-resolved immunofluorometric assays at the Department of Biomedicine, Aarhus 
University, Denmark between November 2017 and May 2018. The analyses were performed 
as previously described35-40 except for a few changes in the H-ficolin and MASP-1 assays. 
Briefly, serum was thawed, diluted in assay buffers and added to microtiter wells 
(FluoroNunc, Thermo ScientificTM, Hvidovre, Denmark) coated with relevant capture 
antibodies, mannan (for MBL assay) or acetylated bovine serum albumin (for H-ficolin 
assay). Standards, samples and controls were added automatically to plates using a Janus® 
Varispan automated work station (PerkinElmer, Waltham, MA, USA). In-house biotinylated 
antibodies, europium-labelled streptavidin (PerkinElmer, Waltham, MA, USA) and 
enhancement solution (Ampliqon, Odense, Denmark) were added in successive steps with 
triple washing in between. The europium fluorescence intensity was detected with a Victor 
X5® fluorometer (PerkinElmer, Waltham, MA, USA). 
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MASP-1 was analysed as previously described by our group,33 except that plates were 
coated with murine anti-MASP-1 antibodies (clone 1H1G6, Genscript, lot no A217100014) 
instead of the previously used antibody. For H-ficolin, acetylated bovine serum albumin was 
used as the capturing agent as described by Hein et al.41 The wells were coated with 10 
μg/ml acetylated bovine serum albumin (Sigma® B2518) diluted in coating buffer (0.1 M 
sodium bicarbonate, pH 9.6 with 0.09% (w/v) sodium azide). Standards, controls and 
samples were diluted in tris-buffered saline with 0.05% Tween-20, 5 mM CaCl2
 and 1 mg/ml 
human serum albumin, and in-house biotinylated mouse anti-human H-ficolin (clone 4H5, 
HyCult® Biotechnology cat# HM2089b) was used as detecting antibody as previously 
described by our group.42 
Each microtiter plate contained three quality controls. All standards, controls and samples 
were added in duplicate, and a coefficient of variation of 15% was accepted. The person 
performing the analysis (JBL) was blinded to placental pathology and IUGR status at the 
time of analysis. 
 
Statistics 
Data were visually assessed for Gaussian distribution using quantile-quantile plots, and 
logarithmic transformation was used if the original data did not follow a Gaussian distribution. 
Since a Gaussian distribution could not be achieved for all lectin pathway proteins, protein 
concentrations were generally displayed as medians with interquartile ranges (IQR). 
Differences in lectin pathway protein concentrations between groups were analysed with 
unpaired t-test if data followed a Gaussian distribution, otherwise with Mann-Whitney test. 
Changes observed during pregnancy within the normotensive pregnancy group were 
analysed using repeated measures analysis of variance or Friedman’s test. Differences in 
protein concentrations before and after delivery within groups were analysed with paired t-
test if data followed a Gaussian distribution, otherwise with Wilcoxon’s matched pairs signed 
rank test. Since this was an exploratory study analysing multiple lectin pathway proteins, and 
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since the size of the cohort was determined in beforehand, a sample size calculation was not 
performed. 
All statistical analyses were performed with Stata® 14 (StataCorp, Texas, USA), and 
graphs were prepared using Prism 7.0 (GraphPad, La Jolla, CA, USA). 
 
Results 
Study population 
In total, serum samples were available from 51 normotensive pregnant women, of which 37 
had a post-delivery sample. For women with preeclampsia, serum samples were available 
for 54 women, of which 51 had a post-delivery sample. Demographic and clinical 
characteristics are shown in Table 1. 
 
Lectin pathway protein serum concentrations 
Lectin pathway protein concentrations in normotensive pregnant women and women with 
preeclampsia at all sampling times are displayed in Supplementary Table 1. Lectin pathway 
protein concentrations (IQR) in healthy non-pregnant women are displayed as dotted lines in 
Figures 1 and 2. 
 
Changes during and after pregnancy 
Normotensive pregnant women 
All lectin pathway proteins except M-ficolin and MASP-3 increased significantly during 
pregnancy in the normotensive group (Figure 1). The median increase from GA 16 to GA 37 
ranged from 11% (IQR: 0-23%) for CL-L1 to 39% (IQR: 27-51%) for MAp19 (all p<0.0001). 
For H-ficolin, the increase occurred primarily from GA 16 to GA 33 (median increase 19% 
(IQR: 11-25%), p<0.0001) with a drop from GA 33 to GA 37. A decrease from GA 37 to after 
delivery was observed for almost all proteins, ranging from 15% (IQR: 1-24%) for H-ficolin to 
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54% (IQR: 48%-76%) for MBL (all p<0.001). An exception was MASP-3, which displayed a 
30% (IQR: 8-44%) increase from GA 37 to after delivery (p<0.001). 
 
Women with preeclampsia 
In the preeclampsia group (Figure 2), a similar pattern was observed as for the normotensive 
group with significant decreases in most protein concentrations after delivery, ranging from 
12% (IQR: -21-31%) for M-ficolin to 58% (IQR: 48-62%) for MASP-1. Exceptions were H-
ficolin and MASP-3 which showed a median increase after delivery of 30% (IQR: 15-65%) 
for H-ficolin and 53% (IQR: 34-81%) for MASP-3, both p<0.0001. MASP-2 did not change 
significantly (p=0.22). 
We also examined the influence of preeclampsia severity on the lectin pathway and 
observed no difference in lectin pathway protein concentrations between women with mild or 
moderate preeclampsia (n=11) and women with severe preeclampsia or HELLP (n=43) 
(p>0.16 for all proteins). 
A proportion of the women with preeclampsia received betamethasone (Celeston®) for 
foetal lung maturation (43%). We observed no difference in lectin pathway protein levels 
between women who received betamethasone (n=23) and women who did not (n=31) (all 
p>0,15), except for M-ficolin which was numerically but not significantly lower in women who 
received betamethasone than women who did not (median 3,373 (IQR: 2,659-5,014) ng/ml 
vs 4,116 (3,372-4,978) ng/ml, p=0.10), and MASP-3 which was lower in women who 
received betamethasone than in women who did not (4,349 (3,803-5,120) vs 5,252 (4,467-
6,206), p=0.03). 
 
Women with preeclampsia versus normotensive pregnant women 
H-ficolin, M-ficolin and MASP-3 concentrations were significantly lower in women with 
preeclampsia than in normotensive pregnant women in late pregnancy, as displayed in 
Figure 2. CL-L1 and MASP-1 concentrations were higher in women with preeclampsia than 
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in normotensive pregnant women. MBL, MAp19, MAp44 and MASP-2 concentrations did not 
differ between women with preeclampsia and normotensive women (all p-values>0.40). 
 
Association between lectin pathway proteins and placental infarction and IUGR 
Lectin pathway protein concentrations in women with and without placental infarction and 
with and without IUGR are shown in Figures 3 and 4. We observed significantly lower 
MASP-3 concentrations in women with ≥10% placental infarctions (n=12) than in women 
with no or <10% placental infarctions (n=80) (median 4,447 (IQR: 4103-5392) ng/ml vs 5,116 
(IQR: 4,343-5,990) ng/ml, p=0.03). Likewise, MASP-3 concentrations were lower in women 
with IUGR (n=21) than in women without IUGR (n=84) (median: 4,545 (IQR: 4,110-5,143) 
ng/ml vs 5,312 (IQR: 4,392-6,244) ng/ml, p=0.04). We also observed lower H-ficolin 
concentrations in women with IUGR than in women without IUGR (median 19,504 (IQR: 
17,968-22,134) ng/ml vs 23,912 (IQR: 20,338-29,440) ng/ml, p=0.009). When examined in 
women with preeclampsia only, we still found that women with ≥10% placental infarctions 
(n=11) had lower MASP-3 than women with no or <10% infarction (n=42) (median 4,349 
(IQR: 4,014-5,143) ng/ml vs 5,006 (IQR: 4,110-5,920) ng/ml, p=0.05). Women with 
preeclampsia and IUGR (n=17) had numerically but not statistically significantly lower 
MASP-3 and H-ficolin than women with preeclampsia without IUGR (n=37) (MASP-3, 
median 4,349 (IQR: 4,014-5,120) ng/ml vs 5,007 (IQR: 4,373-5,846) ng/ml, p=0.11; H-ficolin, 
18,821 (IQR: 17,820-22,046) ng/ml vs 20,635 (17,793-22,481) ng/ml, p=0.22). No significant 
differences were found for the other lectin pathway proteins. 
 
Discussion 
We showed that lectin pathway protein concentrations increased during pregnancy and 
decreased after delivery. Exceptions were MASP-3, which increased after delivery in both 
normotensive pregnant women and women with preeclampsia, and H-ficolin, which 
increased after delivery in women with preeclampsia. H-ficolin, M-ficolin and MASP-3 
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concentrations were lower in women with preeclampsia than in normotensive pregnant 
women. Low MASP-3 concentrations were associated with excess placental infarction and 
IUGR, and low H-ficolin concentrations were associated with IUGR. 
Our results demonstrate that lectin pathway protein concentrations generally increase 
during normal pregnancy and decrease after delivery, to a level similar to healthy non-
pregnant women.33 An exception was MASP-3 which increased after delivery. Our results 
are supported by van de Geijn et al who found an approximate increase of 50% in serum 
MBL during normal pregnancy and a decline again six weeks after delivery.43 Consecutive 
serum concentrations of MASP-1, -2 and -3 and MAp19 and -44 during pregnancy have not 
been described previously. We were not able to follow women with preeclampsia at several 
time points during pregnancy, but we found a similar pattern of higher concentrations in late 
pregnancy and a decline after delivery, except for MASP-3 and H-ficolin, which were low in 
late pregnancy and increased after delivery. Our findings support an upregulation of innate 
immunity during pregnancy, with a return towards pre-pregnancy conditions when the 
maternal circulation is no longer exposed to the placenta.43 
We observed lower concentrations of H-ficolin, M-ficolin and MASP-3 in women with 
preeclampsia than in normotensive pregnant women. This supports previous findings of 
lower H-ficolin levels in pregnancies complicated by preeclampsia as compared with 
normotensive pregnancies.21,27 Yet, M-ficolin and MASP-3 have not been investigated 
previously in pregnancies complicated by preeclampsia, whereas MBL is extensively 
investigated in preeclampsia.17-20,28,29 Some previous studies described increased MBL 
concentrations in preeclampsia compared with normotensive pregnancy17,18 while others 
found no difference.28,29 Our results support the latter. These discrepant findings may be due 
to differences in the employed preeclampsia criteria, the laboratory assays used or the 
statistical power across studies. 
Excess placental infarction and IUGR were associated with lower MASP-3 and H-ficolin 
concentrations, both in the overall study population and in women with preeclampsia alone. 
This contrasts with the results of Halmos et al who found no association between serum H-
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ficolin and IUGR in women with preeclampsia;21 however, the number of women with IUGR 
in their study was low (n=11). No previous study investigated associations between MASP-3 
concentrations and IUGR or placental infarction. Other authors reported an association 
between serum MBL or MBL2 polymorphisms and IUGR;17,19,29 Sziller et al found that the 
MBL2 codon 54 polymorphism associated with lower MBL serum concentrations was 
associated with lower incidence of IUGR in women with preeclampsia,19 and Celik et al 
reported a negative correlation between MBL serum concentrations and birth weight.17 
These findings suggest a protective effect of low serum MBL concentration on the risk of 
IUGR. By contrast, Csuka et al found no difference in MBL-MASP activity between women 
with preeclampsia with and without IUGR;29 however, their study included few IUGR events 
(n=11). We chose a relatively strict definition of IUGR (2 standard deviations below mean 
weight for GA). This definition was chosen since it better reflects an increased risk of 
adverse perinatal outcomes44-47 and reflects the clinical cut-off for intensified antenatal 
surveillance of pregnancies in Denmark, and thus it was deemed more clinically relevant in 
the context of the present study. The use of different IUGR definitions may explain different 
findings between the present study and the work of others. 
Lower concentrations of lectin pathway proteins may reflect decreased synthesis or 
increased consumption. The liver is the main synthesis site for the majority of lectin pathway 
proteins, with the exception of M-ficolin which is synthesised mainly in leukocytes48 and 
MASP-3 which is synthesised throughout the body.49 Lower concentrations of lectin pathway 
proteins may thus be explained by impaired liver function in women with preeclampsia; 
however, it would be expected that all liver-synthesised lectin pathway proteins were lower in 
preeclampsia than in normotensive pregnancy, which was not the case in our study. Thus, 
impaired synthesis cannot fully explain our findings. Wang et al described low serum H- and 
L-ficolin concentrations coupled with evidence of increased placental deposition of H- and L-
ficolin in women with preeclampsia.27 Decreased serum complement factor 4 (C4)50 and 
increased C4d deposition in placentae from women with preeclampsia51,52 has also been 
described. These findings indicate that increased placental complement activation 
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contributes to preeclampsia, as argued by Buurma et al.51 Interestingly, MASP-3 is emerging 
as an activator of the alternative complement pathway,53,54 and Hoffman et al found evidence 
of increased alternative pathway activation in preeclampsia compared with normotensive 
pregnancy.55 We found low H-ficolin and MASP-3 to be associated with preeclampsia but 
also with signs of placental dysfunction such as placental infarction and IUGR. These results 
could be interpreted as a sign of increased placental H-ficolin and MASP-3 deposition in 
women with preeclampsia, placental infarction and IUGR, in accordance with the findings of 
Wang et al.27 However, we do not have data on placental H-ficolin or MASP-3 deposition to 
support this interpretation. This could be a focus point for future studies. Other perspectives 
could be the use of H-ficolin or MASP-3 as early predictive or prognostic markers for 
preeclampsia and related placental dysfunction. These lectin pathway proteins could have 
advantages over e.g. MBL as biomarkers, since their interindividual variation is lower,33,56 
and MASP-3 shows a low diurnal variation.33 However, H-ficolin shows some diurnal 
variation33 and is subjective to changes due to infection and inflammatory conditions,57 which 
limits its clinical usefulness. 
A strength of the present study was the longitudinal sample collection which allowed us to 
assess lectin pathway proteins both during pregnancy and after delivery in a well-described 
study population. We assessed a broad range of lectin pathway proteins, some of which 
have not previously been investigated in normal pregnancy or in preeclampsia. We ensured 
a high validity of the preeclampsia diagnosis through verification by two independent 
obstetricians. Moreover, experienced perinatal pathologists performed the placental 
pathology investigations. However, some limitations should be considered. Two women with 
preeclampsia had gestational diabetes mellitus, which could influence lectin pathway protein 
serum concentrations, as described for non-pregnant diabetic subjects.58,59 However, since 
this was a low proportion of the entire cohort, we assumed that it would not influence our 
results. Four women received low molecular weight heparin during pregnancy, but we have 
previously shown that low molecular weight heparin in prophylactic doses does not influence 
lectin pathway protein plasma concentrations.60 GA was similar but not identical in the 
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normotensive group and the preeclampsia group, and we cannot exclude a possible 
influence on our results. Additionally, for the preeclampsia group, the timing of blood sample 
collection after delivery varied widely. We cannot exclude that glucocorticoid treatment could 
have influenced our results. The effect of glucocorticoid treatment on MASP-3 plasma levels 
is not well investigated; one study found an upregulating effect of dexamethasone on the 
MASP1/3 gene in vitro.61 The time from blood sampling to analysis was long. Nevertheless, 
lectin pathway proteins are stable in serum for several years at -80°C (unpublished results 
from our laboratory), but we cannot rule out that some evaporation may have occurred, 
possibly resulting in higher absolute protein concentrations. However, this increased storage 
time was non-differential across the groups; thus, we consider it unlikely to have influenced 
the main conclusion of our findings. Differences in lectin pathway proteins between early- 
and late onset preeclampsia could have been of interest; however, the women were 
classified according to preeclampsia severity and not onset time; thus it was not possible to 
investigate this issue. Finally, our sample size was moderate; thus, our study may 
underestimate associations between placental infarction or IUGR and lectin pathway 
proteins. 
In conclusion, we found that H-ficolin and MASP-3 serum concentrations were lower in 
the 3rd trimester than after delivery and were lower in women with preeclampsia than in 
normotensive pregnant women in late pregnancy, in contrast to other lectin pathway 
proteins. Furthermore, low MASP-3 concentrations were associated with both placental 
infarction and IUGR, and low H-ficolin concentrations were associated with IUGR. Our 
results indicate a possible involvement of MASP-3 and H-ficolin in the pathogenesis of 
preeclampsia and related placental dysfunction. 
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Tables 
Table 1. Clinical and demographic characteristics on normotensive pregnant women 
and women with preeclampsia. 
  Normotensive pregnant 
women (n=51) 
Preeclampsia (n=54)
Age, years 32.6 ± 3.8 31.6 ± 5.9 
GA at birth, weeks 40+3 (39+2-41+3) 36+2 (33+6-38+0) 
Blood sampling before delivery 
-GA, weeks 
-days before delivery 
Blood sampling after delivery 
-months after delivery 
 
- 
 
- 
 
35+4 (33+0-37+5) 
2 (1-6) 
 
4.4 (0.25-8) 
Parity = 0 26 (51) 39 (72) 
Method of birth 
-vaginal 
-sectio 
 
38 (75) 
13 (25) 
 
17 (31) 
37 (69) 
Preeclampsia severity
-mild/moderate 
-severe 
-HELLP 
 
- 
 
11 (20) 
39 (72) 
4 (7) 
Gestational diabetes mellitus 0 2 
LMWH prophylaxis† 0 4 
Betamethasone before birth 0 (0) 23 (43) 
Preeclampsia in previous pregnancy 
-no 
-yes 
-not relevant (parity = 0) 
 
24 (47) 
1 (2) 
26 (51) 
 
 3 (6) 
12 (22) 
39 (72) 
Symptomatic VTE in current pregnancy‡ 0 (0) 0 (0) 
Symptomatic VTE in previous pregnancy 0 (0) 1 (2) 
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IUGR 4 (8) 17 (31) 
Placental infarction ≥10% 
-no 
-yes 
-data not available 
 
38 (74) 
1 (2) 
12 (24) 
 
42 (78) 
11 (20) 
1 (2) 
Data are presented as either mean ± standard deviation, median (interquartile range) or n 
(%). Abbreviations: GA, gestational age (weeks); HELLP, haemolysis, elevated liver 
enzymes, low platelets; IUGR, intrauterine growth restriction; LMWH, low molecular weight 
heparin; VTE, venous thromboembolism. †Indication for LMWH prophylaxis: known 
thrombophilia, n=2, other indications (immobilisation, previous obstetric complication), n=2. 
‡Data on venous thromboembolism were obtained from medical records. Participants were 
followed until 6 weeks after delivery. 
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Figure legends 
 
Figure 1 
Figure 1. Lectin pathway protein concentration in normotensive pregnant women at 
gestational week 16, 33 and 37 (n=51) and 1 month after delivery (n=37). 
Median with interquartile range is displayed. Dotted lines: Lectin pathway protein 
concentrations in healthy non-pregnant women (n=149), interquartile range. aFriedman's 
test, bRepeated measures analysis of variance with Geisser-Greenhouse correction, 
cWilcoxon's matched-pairs signed-rank test, dPaired t-test. Abbreviations: CL-L1, collectin 
liver 1; GA, gestational age (weeks); MAp19/-44, MBL-associated protein of 19/44 kDa; 
MASP, MBL-associated serine protease; MBL, mannose-binding lectin; p.p., post partum 
(after delivery) 
 
Figure 2 
 Figure 2. Lectin pathway protein concentrations in women with preeclampsia at gestational 
week 36 and after delivery (n=54) and in normotensive pregnant women at gestational week 
37 (n=51). 
Median with interquartile range is displayed. Dotted lines: Lectin pathway protein 
concentrations in healthy non-pregnant women (n=149), interquartile range. aMann-Whitney 
test, bUnpaired t-test with/without Welch's correction, cWilcoxon's matched-pairs signed-rank 
test, dPaired t-test. Abbreviations: CL-L1, collectin liver 1; GA, gestational age (weeks); 
MAp19/-44, MBL-associated protein of 19/44 kDa; MASP, MBL-associated serine protease; 
MBL, mannose-binding lectin; NP, normotensive pregnant women; PE, women with 
preeclampsia. 
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Figure 3 
Figure 3. Lectin pathway protein concentrations in women with placental infarction ≥10% 
(n=12) and no placental infarction or infarction <10% (n=80). 
Median with interquartile range is displayed. aMann-Whitney test, bUnpaired t-test 
with/without Welch's correction. Abbreviations: CL-L1, collectin liver 1; MAp19/-44, MBL-
associated protein of 19/44 kDa; MASP, MBL-associated serine protease; MBL, mannose-
binding lectin. 
 
Figure 4 
Figure 4. Lectin pathway protein concentrations in women with (n=21) and without (n=84) 
intrauterine growth restriction. 
Median with interquartile range is displayed. aMann-Whitney test, bUnpaired t-test 
with/without Welch's correction. Abbreviations: CL-L1, collectin liver 1; MAp19/-44, MBL-
associated protein of 19/44 kDa; MASP, MBL-associated serine protease; MBL, mannose-
binding lectin.  
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